含有黄素的多糖微粒通过改善肠道微生态和调节MAPK/NF-κB/Nrf2/NLRP3通路来缓解DSS诱导的性结肠炎
Lu Wang1, Weiyun Zheng2, Qiuyue Men1
1School of Food Science and Technology, National Engineering Research Center of Seafood, Dalian Polytechnic University, Dalian 116034, PR China.
International journal of biological macromolecules
|October 20, 2024
概括
黄素复合物多糖化微粒 (Cur-CPM) 通过改善黄素吸收和减少炎症来增强肠道健康. 这种新的配方有效地治疗结肠炎症状,并保护肠道屏障.
科学领域:
- 营养科学 营养科学
- 胃肠病学 胃肠病学
- 生物材料科学 生物材料科学
背景情况:
- 黄素 (Cur) 提供了许多健康益处,但其生物可用性较差.
- 开发有效的输送系统对于最大限度地发挥黄素的治疗潜力至关重要.
研究的目的:
- 准备和描述含有黄素的复合型多糖体微粒 (Cur-CPM).
- 评估Cur-CPM在小鼠模型中改善大肠炎的疗效.
- 阐明Cur-CPM对肠道健康益处的潜在机制.
主要方法:
- 使用食品级材料和凝技术制备Cur-CPM.
- 在Cur-CPM的特性和疗效的体外和体内分析.
- 评估DSS治疗小鼠的炎症通路 (MAPK,NF-κB,NLRP3),氧化应激 (Nrf2),肠道屏障完整性和肠道微生物群.
主要成果:
- 与自由黄素相比,Cur-CPM显示黄素在肠道中的停留时间和吸收增加.
- Cur-CPM有效地缓解了结肠炎症状,减少了结肠炎症,并抑制了氧化应激.
- 通过保持粘膜层的完整性和紧密的接口,Cur-CPM改善了肠道屏障功能.
结论:
- 库尔-CPM显著提高了黄素的生物可用性和治疗肠道健康的疗效.
- 库尔-CPM的抗炎和抗氧化特性,以及肠道微生物群调节,有助于其保护作用.
- 治疗-CPM显示为改善肠道健康和管理炎症状况的功能成分有前途.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
01:17Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
322
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
322
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
397
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
397
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
146
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
146
01:29Inflammatory Bowel Disease IV: Pharmacological Management
117
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
117